The First FDA-Approved Intravesical Non-Replicating Gene Therapy for High-Risk Non

The First FDA-Approved Intravesical Non-Replicating Gene Therapy for High-Risk Non–Muscle-Invasive Bladder Cancer

Please join us for a discussion on the role of a novel treatment in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). We will consider the challenges of treating BCG-unresponsive high-risk NMIBC, understand the durability, dosing, and safety profile, as well as review practical considerations for incorporating novel treatment into your clinic.

Dr Aditya Bagrodia

Aditya Bagrodia, MD, FACS Associate Professor, Department of Urology, UC San Diego La Jolla, CA Dr Bagrodia received his MD from the University of Tennessee Health Sciences Center in Memphis, Tenn. He completed his residency in urology at UT Southwestern Medical Center in Dallas, where he also undertook a fellowship in clinical research techniques. Furthering his specialization, Dr Bagrodia completed a fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center in New York City. As a board-certified urologist, Dr Bagrodia has dedicated his practice to the detection, treatment, and prevention of genitourinary cancers, employing both surgical and nonsurgical methods for a range of urologic malignancies. Dr Bagrodia emphasizes personalized treatment plans for his patients, balancing survival and quality of life with the latest treatment options. In his academic role, Dr Bagrodia serves as an associate professor in the Department of Urology at UC San Diego School of Medicine. He leads the genitourinary disease team, training medical students, residents, and fellows. Dr Bagrodia has been a principal investigator on clinical trials and has published extensively, with more than 150 articles in peer-reviewed journals.

AUANews Worthy Opening Slides - Ferring

Duration

00:00:32

Event Details